Articles On Neurotech International (ASX:NTI)

A listed Australian biopharmaceutical development company says it has the potential to provide the world’s first approved cannabinoid drug therapy for neurological disorders, like autism, in children.

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

The ASX rebounded from a sluggish start… but wait, it all dipped again as we were heading out the door Local traders were initially shaken this morning after remarks from Fed’s Powell Aussie defence budget to be given a $50bn boost   The...

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.

Neurotech International (ASX:NTI), has attained a new milestone in its clinical trial for Autism Spectrum Disorder (ASD) – as it now confirms its 54th and final patient has completed their last visit for the Phase II/III NTIASD2 clinical tr...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final...

  Aussie shares set to rise again after a modest tick up on Wall Street Gold price hit a new high Bank of America’s bullish predictions on gold and copper prices   Aussie shares are set to rise again on Wednesday after Wall Street ticked...

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is be...

We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Neurotech International (ASX:NTI) has announced the extension of its Phase 1/2 clinical trial investigating the use of NTI164 in female Rett Syndrome patients and an additional ethics approval.

  Local markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary stocks offset losses in materials and Energy  Small Caps led by LBT Innovations   It’s hard to stay afloat when BHP sinks to a near nine-m...

12-week Phase I/II clinical trial to treat Rett Syndrome with NTI164 broad spectrum cannabinoid drug therapy extended to 52 weeks All 14 female patients to receive NTI164 under care of Associate Professor Carolyn Ellaway Phase I/II 12 week...

Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week dura...

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...

Neurotech International (ASX: NTI) has announced “highly significant” improvements during the extension phase of a clinical trial into the impact of its lead candidate NTI164 on children with paediatric autoimmune neuropsychiatric disorders...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.

Immuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for benefit of patients   Immuron’s record sales Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January pe...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received a 52-week extension to its trial of a potential medicinal cannabis plant extract treatment for children with autism spectrum disorder (ASD)...

  ASX to rise as Dow Jones hits fresh record Chipmaker Arm rises by almost 30pc Bitcoin has topped US$50k   The ASX is poised to rise on Monday after a mixed session in New York. At 8am AEDT, the ASX 200 index futures contract was pointi...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on the progress of its world-first Phase I/II clinical trial examining the daily use of proprietary broad-spectrum cannabinoid dr...

Neurotech says due to often negative publicity around cannabis companies it tends not to promote itself as one Neurotech taking drug development approach to lead product NTI164, meaning it will be registered as a prescription-only BOD Aust...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has been recognised for its breakthrough development in the proposed treatment of paediatric neurological disorders with the grant of a $3.17 million re...

  Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves...

Neurotech International (ASX: NTI) continues to make excellent progress in accelerating its specialist medical solutions for the treatment of neurological disorders. The company is refining the use of its NTI164 treatment to help overcome a...

Paediatric patients with PANDAS/PANS treated with Neurotech’s NTI164 showed marked improvements Anxiety and depression levels in patients reduced by 30% whilst severity of illness sees 18% improvement Results from genomic analysis of patie...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Paediatric neurological disorders specialist Neurotech International (ASX: NTI) has received promising results from its trial of potential treatments for the Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Inf...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Clinical-stage biopharmaceutical company Neurotech International (ASX: NTI) has completed the recruitment of 14 patients into a Phase I/II clinical trial investigating the use of lead candidate NTI164 in females with Rett Syndrome. The 16-w...

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Stockhead’s Top 10 at shortly-before-11-ish, published once our panel of the world’s best chocolatiers have sampled the wares, and deemed them worthy to be displayed in the fanciest windows of the fanciest stores, in the fanciest cities of...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

A unique Australian trial currently being conducted by Neurotech International (ASX: NTI) is looking to make a breakthrough in the treatment of major paediatric neurological disorders. Speaking at a special seminar today, professor Russell...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week   Cannabis stocks ope...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Biopharmaceutical development company Neurotech International (ASX: NTI) has achieved a last patient-last visit (LPLV) milestone for its Phase I/II clinical trial of lead drug NTI164 in children diagnosed with paediatric autoimmune neuropsy...

Futures point to the ASX opening fairly flat this morning on another busy day of reporting. Today, the Bank of Queensland, IGO, Sandfire Resources and Harvey Norman will all release their results. Here are some stocks to watch for you...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has reached a critical milestone with the dosing of the initial patient using its unique treatment for Rett Syndrome. The first patient has now been enr...

The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot...